DAFTAR PUSTAKA

Amerman, E. C., 2016. Human Anatomy & Physiology. 1st Edition. Inggris: Pearson
Education Limited.
Appel, G. B., 2006. Improved outcomes in nephrotic syndrome. Cleveland Clinic
Journal of Medicine, 73(2), pp. 161–167.
Arora, R. & Srivastava, R. N., 2007. Complications of Nephrotic Syndrome in
Children, Apollo Medicine. Indraprastha Medical Corporation Ltd., 4(2), pp.
130–134. doi: 10.1016/S0976-0016(11)60121-X.
Arsita, E., 2017. Pendekatan Diagnosis dan Tata Laksana Sindroma Nefrotik, J.
Kedokteran Medittek, 23(64), pp. 73–82.
Ashley, C. & Dunleavy, A., 2019. The Renal Drug Handbook The Ultimate
prescribing Guide for Renal Practitioners. 5th Edition. London: CRC Press.
Avner, E. D., Harmon, W. E., Niaudet, P., Emma,N. Y.F. & Goldstein,S. L.,. 2016.
Pediatric Nephrology. 7th Edition. London: Springer.
Barreras, A., Pharmd & Gurk-Turner, C. (2003) ‘Angiotensin II receptor blockers’,
BUMC Proceedings, 75246, pp. 123–126.
Baxter, K., 2008. Stockley’s Drug Interactions. 8th Editionn. London: Pharmaceutical
Press.
Blaine, J. 2016. Proteinuria : Basic Mechanisms, Pathophysiology and Clinical.
Switzerland: Springer Nature.
BNF, 2011. British National Formulary. 61th Edition. London: BMJ Group.
Boron, W. F. & Boulpaep, E. L., 2012. Medical Physiology : A Celluler and
Molecular Approach. 2nd Edition. Philadelphia: Elsevier, Inc.
Brunton, L., 2008. Goodman & Gilman Dasar Farmakologi Terapi. Jakarta: Buku
kedokteran ECG.
Brunton, L., Chabner, B. A. & Knollmann, B. C., 2011. Goodman & Gilman’s The
Pharmacological Basis of Therapeutics. 12th Edition. New York.
Brunton, L. L., Hilal-Dandan, R. & Knollmann, B. C., 2018. Goodman & Gilman’s
 The Pharmacological Basis of Therapeutics. 13th Edition. New York:
McGraw-Hill Education.

Bryant, B. & Knight, K., 2015. Pharmacology For Health Professionals. 4th Edition.
Australia. This: Elsevier Inc.
Chanchlani, R. & Parekh, R. S., 2016. Ethnic Differences in Childhood Nephrotic
Syndrome. Frontiers in Pediatrics, 4(39), pp. 1–6. doi:
10.3389/fped.2016.00039.
Chaudhury, A. R., Rajarajan, T., Yousuf1, R., Fernando, E. & Kurien, A. A., 2016.
Lupus Podocytopathy: An Important Differential Diagnosis of Nephrotic
Syndrome in Systemic Lupus Erythematosus. Indian Society of Nephrology.
doi: 10.4103/0971-4065.169566.
Cross, S. S., 2013. Underwood’s Pathology A Clinical Approach. 6th Edition. China:
Elsevier Ltd.
Cupisti, A., Rizza, G. M., D’Alessandro, C., Morelli, E. & Barsotti, G., 2003. Effect of
telmisartan on the proteinuria and circadian blood pressure profile in chronic
renal patients. Biomedicine & Pharmacotherapy, 57, pp. 169–172. doi:
10.1016/S0753-3322(03)00013-1.
Dipiro, J. T., Talbert, R. L., Yee, G. C., Matzke, R. G., Wells, B. G. & Posey, L. M.,
2005. Pharmacotherapy A Pathophysiologic Approach. 6th Edition. New
York: McGraw-Hill Companies, Inc.
Dounousi, E., Duni1, A., Leivaditis, K., Vaios, V., Eleftheriadis, T. & Liakopoulos, V.,
2015. Improvements in the Management of Diabetic Nephropathy. The Review
of Diabetic Studies, 12, pp. 1–12. doi: 10.1900/RDS.2015.12.119.
Duffy, M., Jain, S., Harrell, N., Kothari, N., & Reddi, A. S,. 2015. Albumin and
Furosemide Combination for Management of Edema in Nephrotic Syndrome: A
Review of Clinical Studies. Cells, 4, pp. 622–630. doi: 10.3390/cells4040622.
Elliott, J., Grauer, G. F. & Westropp, J. L., 2017. BSAVA Manual of Canine and
Feline Nephrology and Urology. 3rd Edition. Inggris: British Small Animal
Veterinary Association.
Feehally, J., Floege, J., Tonelli, M., & Johnson, R. J., 2019. Comprehensive Clinical
Nephrology. 6th Edition. China: Elsevier Inc.

Field, M. J., Pollock, C. A. & Harris, D. C., 2010. Systems of The Body The Renal
System Basic Scince and Clinical Conditions. 2nd Edition. London: Elsevier
Ltd.
Fogo, A. B. & Kashgarian, M., 2017. Renal Pathology. 3rd Edition. Philadelphia:
Elsevier Inc.
Fourla, N., Kapellos, G., Pană, C., Fășie, D., & Tuță, L., 2018. 17 Years Old Patient
with Nephritic Syndrome Induced by Systemic Lupus Erythematosus. J Nephrol
Ther, 8(3). doi: 10.4172/2161-0959.1000311.
Gadegbeku, C. A., Gipson, D. S., Holzman, L. B., Ojo, A. O., Song, P. X.K., Barisoni,
L., Sampson, M. G., Kopp, J. B., Lemley, K. V., Nelson, P. J., Lienczewski, C.
C., Adler, S. G., Appel, G. B., Cattran, D. C., Choi1, M. J., Contreras, G.,Dell,
K. M., Fervenza, F. C., Gibson, K. L., Greenbaum, L. A., Hernandez, J. D.,
Hewitt, S. M., Hingorani, S. R., Hladunewich, M., Hogan, M. C., Hogan, S. L.,
Kaskel, F. J., Lieske, J. C., Meyers, K. E. C., Nachman, P. H., Nast, C. C., Neu,
A. M., Reich, H. N., Sedor, J. R., Sethna, C. B., Trachtman, H., Tuttle, K. R.,
Zhdanova, O., Zilleruelo, G. E. & Kretzler, M., 2013. Design of the nephrotic
syndrome study network (NEPTUNE) to evaluate primary glomerular
nephropathy by a multidisciplinary approach. Kidney International, 83, pp.
749–756. doi: 10.1038/ki.2012.428.
Galle, J., 2008. Reduction of proteinuria with angiotensin receptor blockers. Nature
Clinical Practice Cardiovascular Medicine, 5(1), pp. 36–43. doi:
10.1038/ncpcardio0806.
Geary, D. F. & Schaefer, F., 2008. Comprehensive Pediatric Nephrology.
Philadelphia: Mosby, Inc. doi: 10.1016/B978-0-7234-3571-6.00165-2.
Hsu, F., Lin, F. J., Ou, H. T., Huang, S. H., & Wang, C. C., 2017. Renoprotective Effect
of Angiotensin- Converting Enzyme Inhibitors and Angiotensin II Receptor
 Blockers in Diabetic Patients with Proteinuria. Kidney & Blood pressure
Research, 42, pp. 358–368. doi: 10.1159/000477946.
IAI, 2017. ISO Informasi Spesialite Obat Indonesia. Jakarta: Isfi Penerbitan.
Imai, E., Chan, J. C. N., Ito, S., Yamasaki, T., Kobayashi, F., Haneda, M., & Makino,
H., 2011. Effects of olmesartan on renal and cardiovascular outcomes in type 2
diabetes with overt nephropathy : a multicentre , randomised , placebo-controlled
study. Diabetologia, 54, pp. 2978–2986. doi: 10.1007/s00125-011-2325-z.
Iodice, C., Balletta, M. M., Minutolo, R., Giannattasio, P., Tuccillo, S., Bellizzi, V.,
D’amora, M., Rinaldi, G., Signoriello, G., Conte, G., & De Nicola, L., 2003.
Maximal Suppression of Renin-Angiotensin System in Nonproliferative
Glomerulonephritis. Kidney International, 63, pp. 2214–2221. doi:
10.1046/j.1523-1755.2003.00015.x.
Jameson, J. L., Kasper, D. L., Longo, D. L., Fauci, A. S., Hauser, S. L., & Loscalzo, J.,
2018. Harrison’s Principles of Internal Medicine. 20th Edition. New York:
McGraw-Hill Education.
Jin, H., Zhang, H. N., Hou, X. L., Zhang, B., Wu, J., & Zhang, H. B., 2016. Clinical
Study of Double Dose of Valsartan Combined With Tacrolimus in Treatment of
Diabetic Nephropathy. European Review for Medical and Pharmacological
Sciences, 20, pp. 174–179.
Jo, Y. Il, Na, H. Y., Moon, J. Y., Han, S. W., Yang, D. H., Lee, S. H., Park, H. C., Choi,
H. Y., Lim, S. D., Kie, J. H., Lee, Y. K. & Shin, S. K., 2016. Effect of Low-Dose
Valsartan on Proteinuria in Normotensive Immunoglobulin A Nephropathy With
Minimal Proteinuria: A Randomized Trial. Korean Journal of Internal
Medicine, 31(2), pp. 335–343. doi: 10.3904/kjim.2014.266.
Kanda, H., Kubo, K., Tateishi, S., Sato, K., Yonezumi, A., Yamamoto, K., & Mimura,
T., 2005. Antiproteinuric Effect of ARB in Lupus Nephritis Patients With
Persistent Proteinuria Despite Immunosuppressive Therapy. Lupus, 14, pp. 288–
292.
KDIGO, 2012. KDIGO Clinical Practice Guideline for Glomerulonephritis. Official
Journal of The Internastional Society of Nephrology, 2(2).
Kher, K. K., Schnaper, H. W. & Greenbaum, L. A., 2017. Clinical Pediatric
Nephrology. 3rd Edition. Amerika Serikat: CRC Press.
Khider, S. I., Mohamed, A. R., Mahmoud, N. F., & Essame, R., 2017. Nephrotic
Syndrome Knowledge and Health Care Related Practices among School Age
Children and their Mothers. Med. J. Cairo Univ, 85(2), pp. 515–522.

Kliegman, R. M., Lye, P. S., Bordini, B. J., Toth, H., & Basel, D., 2018. Nelson
Pediatric Symptom-Based Diagnosis. Elsevier, Inc.
Kobori, H., Mori, H., Masaki, T., & Nishiyama, A., (2013. Angiotensin II Blockade
and Renal Protection. NIH Public Access, 19(17), pp. 3033–3042.
Kosmadakis, G., Filiopoulos, V., Georgoulias, C., Tentolouris, N., & Michail, S.,
2010. Comparison of The influence of Angiotensin-Converting Enzyme Inhibitor
Lisinopril and Angiotensin II Receptor Antagonist Losartan in Patients With
Idiopathic Membranous Nephropathy and Nephrotic Syndrome. Scandinavian
Journal of Urology and Nephrology, 44, pp. 251–256. doi:
10.3109/00365591003667351.
Lacy, C., Amstrong , L., Goldman , M., & Lance , L., 2009. Drug Formulation
Handbook A Comphehensive Resource For All Clinical and Healthcare
Professionals. 17th Edition. Amerika: American Pharmacists Association.
Laverman, G. D., Remuzzi, G. & Ruggenenti, P., 2004. ACE Inhibition Versus
Angiotensin Receptor Blockade : Which Is Better for Renal and Cardiovascular
Protection ?. J Am Soc Nephrol, 15, pp. 64–70. doi:
10.1097/01.ASN.0000093368.27046.3C.
Lee, H. S., 2013. Pathogenic Role of TGF- β in Diabetic Nephropathy. Journal of
Diabetes and Metabolism, (2155–6156), pp. 1–7. doi: 10.4172/2155-6156.S9-
008.
Mancia, G., 2006. Angiotensin II Receptor Antagonists Current Perspectives
Angiotensin II Receptor Antagonists Current Perspectives. Amerika Serikat:
CRC Press.
Mandal, A. K., 2014. Textbook of Nephrology. 3rd Edition. New Delhi: Jaypee
 Brothers Medical.
McCance, K. L. & Huether, S. E., 2014. Pathophysiology: The Biologic Basis for
Disease in Adults and Children. 7th Edition. Canada: Elsevier Inc.
McCance, K. L. & Huether, S. E., 2019. Pathophysiology The Biologic Basis For
Disease in Adults and Children. 8th Edition. Elsevier Inc.
Merseburger, A. S. & Moul, M. A. K. J. W., 2014. Urology at a Glance. London:
Springer.
Nilawati, G., 2012. Profil Sindrom Nefrotik pada Ruang Perawatan Anak RSUP
Sanglah Denpasar. Sari Pediatri, 14(4), pp. 269–272.
Noone, D. G., Iijima, K. & Parekh, R., 2018. Seminar Idiopathic Nephrotic Syndrome
in Children. The Lancet. Elsevier Ltd, 6736(18), pp. 1–14. doi: 10.1016/S0140-
6736(18)30536-1.
O’Callaghan, C. A., 2009. The Renal System at a Glance. 3rd Edition. Inggris: John
Wiley & Son.
Pagana, katheleen D., Pagana, T. J. & Pagana, T. N., 2015. Mosby’s Diagnostic &
Laboratory Test Reference. 12th Edition. St. Louis: Elsevier Inc.
Pardede, S. O., 2017. Tata Laksana Non Imunosupresan Sindrom Nefrotik pada Anak.
Sari Pediatri, 19(1), pp. 53–62. doi: http://dx.doi.org/10.14238/Sp19.1.2017.53-
62.
Park, S. J. & Shin, J. Il., 2011. Complications of Nephrotic Syndrome. Korean Journal
Pediatrik, 54(8), pp. 322–328. doi: http://dx.doi.org/10.3345/kjp.2011.54.8.322.
Pearce, E. & Handoyo, S., 2017. Anatomi dan fisiologi untuk paramedis. 45th ed.
Jakarta: Prima grafika, pp.299-302.
Ponticelli, C. & Glassock, R. J., 2009. Treatment of Primary Glomerulonephritis.
2nd Edition. New York: Oxford University Press.
Ram, C. V. S., 2010. Angiotensin Receptor Blockers and Diuretics as Combination
Therapy : Clinical Implications. American Journal of Hypertension, 17(3), pp.
277–280. doi: 10.1016/j.amjhyper.2003.09.002.
Robbins, S., & Kumar, V., 1995. Buku ajar patologi II. Edisi ke-4. Jakarta: Buku
Kedokteran .
Robbins, S. L., Kumar, V., & Cotran, R. S., 2010. Robbins and Cotran pathologic
basis of disease. Philadelphia, PA, Saunders/Elsevier.
Sabbah, Z. Al, Mansoor, A. & Kaul, U., 2013. Angiotensin Receptor Blockers -
Advantages of the New Sartans. Journal of The Association of Physicans of
India, 61, pp. 28–34.
Schena, F. P. & Gesualdo, L., 2005. Pathogenetic Mechanisms of Diabetic
Nephropathy. American Society of Nephrology, 16, pp. 30–33. doi:
10.1681/ASN.2004110970.
Seigneux, S. De & Martin, P., 2009. Management of Patients With Nephrotic
Syndrome. Swiss Med Wkly, 139, pp. 416–422.
Setiati, S., Alwi, A., Sudoyo, A. W., Simadibrata, M., Setiyohadi, B., & Syam A. F.,
2014. Buku Ajar Ilmu Penyakit dalam. Edisi Ke-6. Jakarta: InternaPublishing.
Sherwood, L., 2016. Human Physiology From Cells to Systems. Canada: Cengage
Learning.
Sica, D. A. & Gehr, T. W. B., 2002. The Pharmacokinetics and Pharmacodynamics of
Angiotensin-Receptor Blockers in End-Stage Renal Disease. Journal of the
Renin- Angiotensin- Aldosterone System, 3(4), pp. 247–254. doi:
10.3317/jraas.2002.046.
Singh, A. K. & Loscalzo, J., 2019. The Brigham Intensive Review of Internal
Medicine. 3rd Edition. Philadelphia: Elsevier Inc.
Siswandono, 2016. Kimia Medisinal. Edisi ke-2. Surabaya: Airlangga Unversity
Press.
Stuart, R., 2012. A rare cause of nephrotic syndrome in autosomal-dominant polycystic
kidney disease. Clinical Kidney Journal, 2(2), pp.136-138.
Sweetman, S. C., 2009. Martindale: The Complete Drug Reference. 36th Edition.
London: Pharmaceutical Press.
Swiatecka-urban, A., Woroniecki, R. P. & Kaskel, F. J., 2017. Nephrotic Syndrome
in Pediatric Patients. Frontiers in Pediatrics. doi: 10.3389/978-2-88945-298-9.
Tazkarji, B. & Ganeshamoorthy, A., 2015. Angiotensin-Converting Enzyme Inhibitors
vs. Angiotensin Reseptor Blockers. American Family Physician, 91(3), pp.
 193–194.
Teeninga, N., 2013. Glucocorticoid Treatment in Childhood Nephrotic Syndrome
Weighing The Cornerstone. Nederland: Erasmus Universiteit Rotterdam.
Thomas, S. & Karalliedde, J., 2015. Diabetic nephropathy. Medicine. Elsevier Ltd, pp.
1–6. doi: 10.1016/j.mpmed.2014.10.007.
Toto, R., 2001. Angiotensin II Subtype 1 Receptor Blockers and Renal Function. Arch
Intern Medical, 161, pp. 1492–1499.
Trihono, P. P., Alatas, H., Tambunan, T., & Pardede, S. O., 2012. Konsensus Tata
Laksana Sindrom Nefrotik Pada Anak. Edisi Ke-2. Jakarta: Badan Penerbit
Ikatan Dokter Anak Indonesia.
Turner, N., Lameire, N., Goldsmith, D. J., Winearls, C. G., Himmelfarb, J., & Remuzzi,
G., 2016. Oxford Textbook of Clinical Nephrology. 4th Edition. Inggris:
Oxford University Press.
UNC Kidney Center, 2018. AL Amyloidosis. UNC Kidney Center. Available at:
https://unckidneycenter.org/kidneyhealthlibrary/glomerular-disease/al-
amyloidosis/. Diakses tanggal: 17 February 2019.
UNC Kidney Center, 2018. Membranous Nephrophathy, UNC Kidney Center.
https://unckidneycenter.org/kidneyhealthlibrary/glomerular-
disease/membranous-nephropathy/. Diakses tanggal 31 Januari 2019.
Unger, T. & Scholkens, B. A., 2004. Handbook of Experimental Pharmacology.
New York: Springer.
Vaziri, N. D., 2016. Disorders of lipid metabolism in nephrotic syndrome: mechanisms
and consequences. Kidney International. Elsevier Inc, pp. 1–12. doi:
10.1016/j.kint.2016.02.026.
Vivian, E. & Mannebach, C., 2013. Therapeutic approaches to slowing the progression
of diabetic nephropathy – is less best ? Pathophysiology of diabetic nephropathy.
Drug in Context, pp. 1–12. doi: 10.7573/dic.212249.
Wang, J. & Mao, J., 2016. The Etiology of Congenital Nephrotic Syndrome: Current
Status and Challenges. World J Pediatrik, 12(2), pp. 149–158. doi:
10.1007/s12519-016-0009-y.
Yamashiro, A., Uchida, T., Ito, S., Oshima, N., Oda, T., & Kumagai, H., 2016.
Complete Remission of Minimal Change Disease Following an Improvement of
Lung Mycobacterium avium Infection. Internal Medicine, 55, pp. 2669–2672.
doi: 10.2169/internalmedicine.55.6885.